Van ECK Associates Corp Has $61,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Van ECK Associates Corp reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 22.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 664 shares of the medical instruments supplier’s stock after selling 197 shares during the period. Van ECK Associates Corp’s holdings in LeMaitre Vascular were worth $61,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Legato Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 2.1% in the fourth quarter. Legato Capital Management LLC now owns 23,178 shares of the medical instruments supplier’s stock valued at $2,136,000 after acquiring an additional 476 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of LeMaitre Vascular by 48.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after buying an additional 4,330 shares in the last quarter. Shaker Investments LLC OH raised its position in shares of LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after buying an additional 112 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of LeMaitre Vascular in the fourth quarter worth $150,000. Finally, Copeland Capital Management LLC raised its position in shares of LeMaitre Vascular by 0.7% in the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock worth $107,990,000 after buying an additional 8,623 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of research analyst reports. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Barrington Research increased their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Oppenheimer reiterated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Stock Down 1.3 %

Shares of LMAT opened at $99.63 on Monday. The company has a market capitalization of $2.24 billion, a P/E ratio of 54.44, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. The firm has a 50 day moving average of $96.03 and a 200 day moving average of $94.29. LeMaitre Vascular, Inc. has a twelve month low of $59.87 and a twelve month high of $109.58.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.